Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: A phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group

European Journal of Cancer

Volumn 40, Issue 14, 2004, Pages 2077-2081

  Van Rijswijk, R E N ^a   Jeziorski, K ^b   Wagener, D J Th ^c   Van Laethem, J L ^d   Reuse, S ^e   Baron, B ^e   Wils, J ^f  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASME HOSPITAL   (Belgium)

^e EORTC DATA CENTER   (Belgium)

^f LAURENTIUS HOSPITAL   (Netherlands)

Author keywords

Fluorouracil; Leucovorin; Pancreatic neoplasms drug therapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ALOPECIA; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HAND FOOT SYNDROME; HUMAN; INFUSION; LETHARGY; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 4444346409     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.06.012     Document Type: Article

References (27)

1. Connolly M.M., Dawson P.J., Michelassi F., Moossa A.R., Lowenstein F. Survival of 1001 patients with carcinoma of the pancreas. Ann. Surg. 206:1987;366-373
2. Glimelius B. Chemotherapy in the treatment of cancer of the pancreas. J. Hepatobiliary Pancreat. Surg. 5:1998;235-241
3. Kozuch P., Petryk M., Bruckner H.W. A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. Hematol. Oncol. Clin. North Am. 16(1):2002;123-138
4. Wils J.A., Kok T., Wagener D.J., Selleslags J., Duez N. Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer. 29A:1993;203-204
5. Wils J.A., Kok T., Wagener D.J., Francois E., Selleslags J., Duez N. Phase II trial with ifosfamide in pancreatic cancer. Eur. J. Cancer. 29A:1993;290
6. Wils J., Bleiberg H., Blijham G., et al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur. J. Cancer Clin. Oncol. 21:1985;191-194
7. Wils J., Bleiberg H., Dalesio O., et al. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. Eur. J. Cancer Clin. Oncol. 23:1987;1017-1018
8. Wils J., Bleiberg H., Buyse M., et al. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. Eur. J. Cancer Clin. Oncol. 25:1989;1119-1120
9. Hansen R., Quebbeman E., Ritch P., Chitambar C., Anderson T. Continuous 5-fluorouracil infusion in carcinoma of the pancreas: a phase II study. Am. J. Med. Sci. 295:1988;91-93
10. Rubin J., Gallagher J.G., Schroeder G., et al. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer. 78:1996;1888-1891
11. Choi C.W., Choi I.K., Seo J.H., et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreaticbiliary tract adenocarcinomas. Am. J. Clin. Oncol. 23:2000;425-428
12. DeCaprio J.A., Mayer R.J., Gonin R., Arbuck S.G. Fluorouracil and highdose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J. Clin. Oncol. 9:1991;2128-2133
13. Tajiri H., Yashimori M., Okazaki N., Miyaji M. Phase II study of continuous 5-fluorouracil in advanced pancreatic cancer. Oncology. 48:1991;18-21
14. Maisey N., Chau I., Cunningham D., et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J. Clin. Oncol. 20:2002;3130-3136
15. Meta-analysis group in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16, 301-8
16. Köhne C.H., Schoffski P., Wilke H., et al. Effective biomodulation by leucovorin of highdose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J. Clin. Oncol. 16:1998;418-426
17. Weh H.J., Wilke H.J., Dierlamm J., et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann. Oncol. 5:1994;233-237
18. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 10:1989;1-10
19. The Advanced Colorectal Cancer Meta-analysis Project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903
20. Thirion P., Cunningham D., Findlay M., et al. Pooled analysis of phase II trials with low-dose 5-fluorouracil continuous infusion as a second-line chemotherapy in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;272a. [abstract]
21. Falcone A., Allegrini G., Lencioni M., et al. Protracted continuous infusion of 5-fluorouracil and lowdose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolusbased chemotherapy: a phase II study. Cancer Chemother. Pharmacol. 44(2):1999;159-163
22. Kuhn J.G. Fluorouracil and the new oral fluorinated pyrimidines. Ann. Pharmacother. 35:2001;217-227
23. Berlin J.D., Adak S., Vaughn D.J., et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology. 58:2000;215-218
24. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson 3rd A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 20:2002;3270-3275
25. Cascinu S., Silva R.R., Barni S., et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br. J. Cancer. 80:1999;1595-1598
26. Jovtis S., Marantz A., Almira E., et al. Phase II trial of gemcitabine (GEM), 5-fluorouracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer (PC). Eur. J. Cancer. 35(Suppl. 4):1999;S157. [abstract]
27. Lutz M.P., Koniger M., Muche R., et al. A phase II study of weekly 24h infusion of highdose 5fluorouracil in advanced pancreatic cancer. Z. Gastroenterol. 37:1999;993-997